Stock Exchange Release,
Financial Statement Bulletin,
This release is a summary of
October-
· Net sales totaled
· Operating profit was
· EBITDA was
·
· The currency-adjusted growth of net sales in October-December was 70.1%, or 2.1 percentage points weaker than reported
· As a result of strong cash flow, the Group is again almost net debt free
· Undiluted earnings per share came to
·
January-
· Net sales totaled
· Operating profit was
· EBITDA was
· Operating profit and EBITDA were weighed down by non-recurring acquisition costs amounting to
· Operating profit adjusted by non-recurring acquisition costs and the impact of the acquisition cost of CenterVue's inventories was
· Adjusted operating profit was 31.0 (33.3) % of net sales
· EBITDA adjusted by non-recurring acquisition costs and the impact of the acquisition cost of CenterVue's inventories was
· The currency-adjusted growth of net sales in January-December was 58.6%, or 2.8 percentage points weaker than reported
· Undiluted earnings per share came to
·
· The company carried out a directed share issue for selected institutional investors in an accelerated bookbuild offering, whereby the company collected new capital totaling
· In addition, the company took out a bank loan amounting to
· The Board of Directors will propose to the Annual General Meeting of
Key consolidated figures, EUR million
Oct-Dec/ Oct-Dec/ Change Jan-Dec/ Jan-Dec/ Change
2019 2018 % 2019 2018 %
Net sales 14.9 8.7 72.2 49.5 30.7 61.4
Operating 5.2 3.0 72.9 12.6 10.2 23.4
profit, EBIT
Operating profit 34.9 34.8 0.2 25.5 33.3 -7.8
-%, EBIT
Adjusted 5.2 3.0 72.9 15.4 10.2 50.5
operating
profit, EBIT
Adjusted 34.9 34.8 0.2 31.0 33.3 -2.2
operating profit
-% EBIT
EBITDA 5.8 3.2 81.6 14.6 10.8 36.0
EBITDA, % 38.6 36.6 2.0 29.5 35.1 -5.5
Adjusted EBITDA 5.8 3.2 81.6 17.4 10.8 61.7
Adjusted EBITDA 38.6 36.6 2.0 35.1 35.1 0.1
-%
Return on 9.4 17.6
investment 22.6 59.5
(ROI), %
Return on equity 9.0 14.0 22.7 47.6
(ROE)*, %
Earnings per 0.143 0.100 0.365 0.339
share, undiluted
2019 2018 %
Equity ratio, % 58.6 81.8 -23.2
Net gearing, % 3.4 -55.6 59.0
* The reference figures for return on investment, % (ROI) and return on equity, % (ROE) have been updated since the company has shifted its calculation to review period specific (3 months / 12 months) earnings of key figures.
Financial guidance for 2020
"
I am very pleased that the acquisition process, has been successfully completed and the integration work has progressed in a highly positive spirit. All the major integration-related projects have proceeded smoothly and will be completed during the first half of 2020. CenterVue's organization has welcomed the new owner with open arms. The ability and willingness to work together across organizational and national boundaries has been admirable. The next major step is to define our brand strategy together.
The year 2019 was another strong year for Icare, which makes devices for measuring intraocular pressure. A major event was the launch of the new ic200 intraocular pressure measurement device in
It is extremely important for us to keep our product portfolio viable. All our current products are less than five years old, which indicates that our product portfolio is up-to-date. We invest heavily in the lifecycle of our products. A good example of this is the Eidon FA fundus imaging device, launched in early 2019, which provides ultra-high-resolution images and videos of fundus fluorescein angiography. At the end of the year, we launched a new-generation fundus imaging device in
Major changes in EU regulatory requirements and audit practices have kept us as well as other companies in our industry busy. The new European Medical Device Regulation (MDR) Decree will take effect in
In 2019, we also defined our corporate responsibility priorities, which are based on our strategic guidelines and the value we create for stakeholders, society, the environment, and the climate. In every aspect of our operations, we take into account the special characteristics of the business and operating environment in the field of health technology and support the
Our outlook is positive. At the start of the new year, we will continue to focus on closely monitoring the progress of various elements of integration. Our aim is to further strengthen our position in ophthalmology. Our strong product development program and new products create an excellent foundation for future growth. We believe that the synergies achieved through the acquisition, especially in terms of sales and marketing and the supply chain, will allow us to further strengthen both our competitiveness and market position. I would like to express my thanks for our success in 2019 to our highly motivated personnel, customers, partners, trusted distributors, owners, and other stakeholders, who have all helped build the foundation for our growth."
Results briefing
Board of Directors
For further information, please contact:
timo.hilden@revenio.fi
robin.pulkkinen@revenio.fi
www.revenio.fi
DISTRIBUTION:
Principal media
www.revenio.fi
The
The
The common denominators of
In 2019, the Group's net sales totaled EUR 49.5 million, with its operating margin standing at 25.5%.
https://news.cision.com/revenio-group-oyj/r/revenio-group-corporation--financial-statement-bulletin--january-1---december-31--2019,c3039908
https://mb.cision.com/Public/17714/3039908/b73d580c11a48196.pdf
(c) 2020 Cision. All rights reserved., source